Diversified Trust Co Boosts Morgan Stanley Stake 63.9% to $7.67 Million
Diversified Trust Co lifted its stake in Morgan Stanley by 63.9% to 48,243 shares worth $7.67 million in Q3, according to an SEC filing. Vanguard Group retains a 119.1 million-share position valued at $16.78 billion, contributing to 84.19% institutional ownership.
1. Institutional Stake Increases Highlight Confidence
In the third quarter, Diversified Trust Co. lifted its holding in Morgan Stanley by 63.9%, adding 18,800 shares to reach 48,243 shares valued at $7.67 million. Vanguard Group increased its position by 1.1%, purchasing 1.35 million additional shares to hold 119.12 million shares worth $16.78 billion. Fisher Asset Management added 749,150 shares to bring its total to 24.05 million shares valued at $3.39 billion. Norges Bank established a new position in the firm with a $2.23 billion investment. Collectively, hedge funds and institutional investors now own 84.19% of the company’s outstanding shares.
2. Third-Quarter Results Exceed Expectations
For the quarter ended October 15, the firm reported earnings per share of $2.80, outperforming consensus forecasts by $0.73. Revenues rose 18.5% year-over-year to $17.98 billion, surpassing analyst estimates by $1.56 billion. The return on equity stood at 16.40% while the net margin reached 13.85%. On a trailing twelve-month basis, the company’s debt-to-equity ratio is 3.27, with a current ratio and quick ratio both at 0.79, reflecting solid capital structure and liquidity metrics.
3. Dividend Lift Demonstrates Commitment to Shareholders
The board approved a quarterly dividend of $1.00 per share, payable to shareholders of record as of October 31 and distributed on November 14. This payout equates to an annualized dividend of $4.00 and a yield of 2.2%. The dividend coverage, measured by the payout ratio, stands at 41.03%, underscoring the firm’s balance between rewarding investors and retaining capital for growth initiatives.
4. Analyst Consensus Skews Positive
Eleven brokerages have recently adjusted their recommendations, with three analysts issuing Strong Buy ratings, eight assigning Buy ratings and seven maintaining Hold opinions. The consensus target price across these research reports is $174.77. Notable revisions include a target raise from $184 to $202 by Keefe, Bruyette & Woods and an upgrade to Outperform by Wolfe Research with a $198 price objective. The current aggregate sentiment signals a Moderate Buy stance, reinforcing momentum investor interest in the stock.